Highlights

  • EBOS Group Limited (ASX:EBO) recorded FY26 Revenue of AUD 13.487 billion.
  • Underlying EBITDA rose 5.0% to AUD 614 million; underlying NPAT fell 3.1%.
  • The AUD 360 million distribution-centre renewal programme reached completion in FY26.
  • FY27 underlying EBITDA guidance of AUD 635–655 million was reaffirmed in October.

EBOS Group Limited distributes pharmaceutical, medical and healthcare products and operates pharmacy-support, medical technology and animal care businesses across Australasia and parts of Asia. On November 17, 2026, its shares (ASX:EBO) traded at AUD 18.06, down 0.17% during the session. The group enters FY27 after completing a major distribution infrastructure programme, while its October annual-meeting update maintained Earnings guidance despite continued fuel and currency cost pressures.

Healthcare Distribution and Animal Care Operations

EBOS (ASX:EBO) reports through Healthcare and Animal Care segments. Healthcare includes Symbion and other medicines distribution operations, retail pharmacy brands, contract logistics, hospital supplies and medical technology. The businesses serve community pharmacies, hospitals, healthcare providers and surgical teams across Australia, New Zealand, Southeast Asia and Hong Kong.

Its retail pharmacy activities include the TerryWhite Chemmart network. Animal Care covers veterinary wholesaling, pet nutrition and consumer animal-health brands, including Black Hawk and VitaPet. These businesses operate through different customer channels, with wholesale medicine distribution influenced by volume, product mix and delivery costs, while pet products also depend on retail distribution and consumer purchasing patterns.

Distribution Network Completed and October Trading Update

In August 2026, EBOS confirmed completion of its four-year AUD 360 million distribution-centre renewal programme. Its eight new facilities were operational by the end of FY26, shifting management’s focus towards utilisation and productivity rather than another major infrastructure build. The company also reported approximately AUD 145 million in FY26 capital expenditure.

At its October 2026 annual meeting, EBOS (ASX:EBO) said first-quarter FY27 growth had continued across the divisions. Productivity at the Kemps Creek distribution centre was approximately 20% higher than the former Greystanes site, against a targeted uplift of about 30% by the end of FY27. The company also said its Chemist Warehouse New Zealand wholesaling contract had been extended, with volumes scheduled to reduce progressively through FY28.

Retail Pharmacy Brands reported a network of approximately 790 stores during the first quarter. Management also highlighted medical technology supplier relationships, recently acquired businesses and sales activity in Black Hawk and VitaPet. Group-wide procurement, support-office and supply-chain coordination initiatives are under development, with incremental financial benefits expected from FY28.

FY26 Financial Results and Divisional Performance

For the year ended June 30, 2026, EBOS (ASX:EBO) recorded revenue of AUD 13.487 billion, 9.9% above FY25. Gross Operating Revenue rose 6.5% to AUD 1.743 billion. Underlying earnings before interest, tax, Depreciation and Amortisation (EBITDA) increased 5.0% to AUD 614 million, while underlying net profit after tax fell 3.1% to AUD 250 million as depreciation, amortisation and finance costs increased. Statutory net profit after tax rose 4.7% to AUD 225 million.

Healthcare revenue grew 8.5% to AUD 12.580 billion and underlying EBITDA increased 3.2% to AUD 516 million. Community pharmacy activity benefited from Demand for GLP-1 and other higher-value medicines; however, product mix and pharmacy competition affected margins. The segment also reported higher fuel costs and foreign-exchange pressures, alongside softer capital-equipment sales in parts of Asia.

Animal Care revenue increased 34.6% to AUD 907 million, with underlying EBITDA up 11.6% to AUD 138 million. Acquired operations contributed to reported growth, while branded pet-food and veterinary distribution activities also expanded. The segment’s underlying EBITDA Margin declined to 15.3% from 18.4%, partly reflecting a greater proportion of wholesale revenue following Acquisition activity.

The group ended FY26 with a Leverage Ratio of 2.1 times, within its 1.7–2.3 times target range. Return on capital employed was 12.8%, down from 13.0%. Its final Dividend was maintained at NZ 61.5 cents per share.

FY27 Guidance and Operating Conditions

EBOS (ASX:EBO) reaffirmed its FY27 guidance in October: underlying EBITDA of AUD 635–655 million, Capital Expenditure of approximately AUD 100 million, depreciation and amortisation of AUD 152–162 million and net finance costs of AUD 138–148 million. Management expects EBITDA and net profit growth to be weighted towards the second half of FY27.

Fuel and currency movements remain relevant. At the October meeting, the company reported that average diesel prices had increased approximately 20% in the period discussed, while Australian-dollar appreciation against the New Zealand dollar had added translation pressure. Changes to Community Service Obligation funding and ongoing medicine demand are also relevant to healthcare distribution earnings.

Risks and Near-Term Monitoring Points

Wholesale pharmacy competition, distribution costs, exchange-rate changes and the mix of high-value medicines can affect group margins. The new warehouse network must deliver the expected productivity gains, while acquisitions bring integration and execution requirements. Capital expenditure is expected to decline, but depreciation and financing charges remain elevated following the Investment cycle.

Investors can monitor the FY27 half-year results for Kemps Creek productivity, cost pressures, divisional earnings and updated capital spending. Further detail on group-wide efficiencies is expected with the half-year reporting. The pace of the New Zealand contract wind-down and developments in animal care product distribution are additional operational measures.

Key Insights

EBOS (ASX:EBO) reported higher FY26 revenue and EBITDA alongside lower underlying net profit. Completion of the distribution-centre programme changes the focus to capacity utilisation, cash generation and delivery against the reaffirmed FY27 earnings range. The next financial update will provide a clearer measure of whether productivity initiatives are offsetting fuel, currency and competitive pressures.